

Deciphering virus-induced cancer cell death in B-cell malignancies

CSS

Offer description

Nantes-Angers Cancer and Immunology Research Center (CRCINA, www.crcina.org), is a multidisciplinary cancer research center supported by INSERM, CNRS, Nantes and Angers Universities, and organized into 17 teams located at Nantes or Angers. CRCINA is the main stakeholder of SIRIC ILIAD (www.siric-iliad.com), an INCa-certified multidisciplinary research project in nuclear (Tharget) and cellular (Pister) oncology in the field of breast cancer and multiple myeloma.

The team “Targeting Bcl2 and p53 networks in multiple myeloma and mantle cell lymphoma” directed by Martine Amiot and Catherine Pellat (Team 10 in CRCINA) studies the regulations of Bcl2 and p53 networks in multiple myeloma and mantle cell lymphoma in order to target resistance. The team, which has an internationally recognized expertise in the field of mitochondrial dependent cell death and its targeting with BH3 mimetics, wishes to increase its expertise by implementing research in virus-induced cell death to overcome p53 and mitochondrial resistance.

SIRIC ILIAD is offering a 2-year Research Fellowship to study the mechanisms of cancer cell death induced by oncolytic viruses (PISTER program) in team 10.

Researcher profiles

- First-Stage Researcher (*PhD candidate*)
- Young Researcher (*with less than 4 years research experience after PhD*)
- Established Researcher (*with more than 4 years research experience*)
- Senior Researcher

Research Fields (2 max.)

- | | |
|---|---|
| <input checked="" type="checkbox"/> Biological Sciences | <input type="checkbox"/> Medical Sciences |
| <input type="checkbox"/> Chemistry | <input type="checkbox"/> Neurosciences |
| <input type="checkbox"/> Computer Science | <input type="checkbox"/> Pharmacological Sciences |
| <input type="checkbox"/> Engineering | <input type="checkbox"/> Physics |
| <input type="checkbox"/> Environmental Science | <input type="checkbox"/> Technology |
| <input type="checkbox"/> Ethics in Health Sciences | <input type="checkbox"/> Other (specify): |

Main Activities

- Basic/translational cancer research investigating the molecular vulnerabilities of tumor ecosystem to oncolytic viruses. SIRIC ILIAD offers access to primary cells (with biological and clinical characteristics) and CRCINA offers access to all cutting-edge technologies including high-throughput tools (scRNA-Seq).

Associated Activities

- The candidate will join Team 10 CRCINA (Targeting Bcl2 and p53 networks in multiple myeloma and mantle cell lymphoma) and benefit from established expertise in cell death and support of the team.

Specific Requirements or Constraints

- The applicant will be expected to be both eligible and competitive for external funding and to apply for grant/fellowship support during the 2-year term, with the intention that this will lead to a tenured position.

Skills/Qualifications

- The candidate is expected to be autonomous and motivated. A strong expertise in cell and molecular biology. Expertise in malignant hematology and in analysis of high-throughput data would be helpful. Teamwork skills are mandatory.

Required Experience 0 to 2 years 2 to 4 years 4 to 10 years >10 years

Fields:

Required Education Level or Diploma

- PhD

Required Languages

- English

Hosting Unit

Code UMR 1232

Name Nantes-Angers Cancer and Immunology Research Center (CRCINA)

Director Marc Grégoire

Composition

Address CRCINA - Institut de Recherche en Santé de l'Université de Nantes - 8 quai Moncouso - BP 70721 - 44007 Nantes cedex 1

Website <http://www.crcina.org/>

Contract

Type Principal Investigator

Duration 2 years

Salary

Envisaged Start Date January 2021

Application

Applicants must send a CV and a cover letter to:

Catherine Pellat (Catherine.pellat-deceunynck@inserm.fr)

Contact for further information (name, telephone/mail):

Catherine Pellat (Catherine.pellat-deceunynck@inserm.fr)

Deadline for application:

December 2020